/
Oncology
Colon Cancer
53
Pipeline Programs↗
73
Active Trials↗
42
Companies Involved↗
Colon Cancer is a moderately active landscape with 53 programs across 42 companies. The most active players are Mirati Therapeutics Inc., Sapience Therapeutics, Pheon Therapeutics. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 14
Phase 218
Phase 319
Approved
No programs
Analysis
Modality Breakdown
64%
Small molecule
32 of 50 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 96% of 53 pipeline programs.
Analysis
Trial Status
202
clinical trials
Completed73 · 36%
Recruiting38 · 19%
Unknown status30 · 15%
Active, not recruiting19 · 9%
Terminated18 · 9%
Not yet recruiting15 · 7%
Other9 · 4%
Clinical Trials
Trial Activity
202 trials
RETROSPECTIVE OBSERVATIONAL STUDY OF CHEMOTHERAPY IN ELDERLY PATIENTS IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
Recruiting·—·N/A·NCT06840977·51 enrolled
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)